Monoclonal Antibody Shows Promise in Mixed Dyslipidemia

Via Peters

MILAN — A single dose of a monoclonal antibody against an inhibitor of an enzyme involved in triglyceride degradation appears to substantially lower triglyceride and cholesterol levels, suggests a phase 1, first-in-human trial. LY3475766 is a monoclonal antibody against the angiopoietin-like protein (ANGPTL)3/8 complex, a potent inhibitor of lipoprotein lipase, and […]